

Cholinergic Modulation of Locomotion and Striatal Dopamine Release Is Mediated by $\alpha 6\alpha 4^*$ Nicotinic Acetylcholine Receptors

Ryan M. Drenan,¹ Sharon R. Grady,² Andrew D. Steele,¹ Sheri McKinney,¹ Natalie E. Patzlaff,² J. Michael McIntosh,^{3,4} Michael J. Marks,² Julie M. Miwa,¹ and Henry A. Lester¹

¹California Institute of Technology, Pasadena, California 91125, ²Institute for Behavioral Genetics, University of Colorado at Boulder, Boulder, Colorado 80309, and Departments of ³Psychiatry and ⁴Biology, University of Utah, Salt Lake City, Utah 84112

Dopamine (DA) release in striatum is governed by firing rates of midbrain DA neurons, striatal cholinergic tone, and nicotinic ACh receptors (nAChRs) on DA presynaptic terminals. DA neurons selectively express $\alpha 6^*$ nAChRs, which show high ACh and nicotine sensitivity. To help identify nAChR subtypes that control DA transmission, we studied transgenic mice expressing hypersensitive $\alpha 6^{L9'S^*}$ receptors. $\alpha 6^{L9'S^*}$ mice are hyperactive, travel greater distance, exhibit increased ambulatory behaviors such as walking, turning, and rearing, and show decreased pausing, hanging, drinking, and grooming. These effects were mediated by $\alpha 6\alpha 4^*$ pentamers, as $\alpha 6^{L9'S^*}$ mice lacking $\alpha 4$ subunits displayed essentially normal behavior. In $\alpha 6^{L9'S^*}$ mice, receptor numbers are normal, but loss of $\alpha 4$ subunits leads to fewer and less sensitive $\alpha 6^*$ receptors. Gain-of-function nicotine-stimulated DA release from striatal synaptosomes requires $\alpha 4$ subunits, implicating $\alpha 6\alpha 4\beta 2^*$ nAChRs in $\alpha 6^{L9'S^*}$ mouse behaviors. In brain slices, we applied electrochemical measurements to study control of DA release by $\alpha 6^{L9'S^*}$ nAChRs. Burst stimulation of DA fibers elicited increased DA release relative to single action potentials selectively in $\alpha 6^{L9'S^*}$, but not WT or $\alpha 4KO/\alpha 6^{L9'S^*}$, mice. Thus, increased nAChR activity, like decreased activity, leads to enhanced extracellular DA release during phasic firing. Bursts may directly enhance DA release from $\alpha 6^{L9'S^*}$ presynaptic terminals, as there was no difference in striatal DA receptor numbers or DA transporter levels or function *in vitro*. These results implicate $\alpha 6\alpha 4\beta 2^*$ nAChRs in cholinergic control of DA transmission, and strongly suggest that these receptors are candidate drug targets for disorders involving the DA system.

Introduction

Dopamine (DA) transmission, both at cell bodies situated in the midbrain and at presynaptic terminals in the striatum and prefrontal cortex, is tightly regulated by cholinergic systems. Patients with neural disorders involving DA signaling may benefit from therapies that augment or reduce cholinergic control over DA release. For example, stimulating DA release from residual DA terminals with nicotinic ACh receptor (nAChR) agonists may be an effective treatment for Parkinson's disease (PD) (Quik and McIntosh, 2006). Conversely, the use of antagonists or weak partial agonists at midbrain nAChRs may be an effective strategy for smoking cessation drugs such as varenicline (Coe et al., 2005).

Developing and further refining such agonists, however, requires a better understanding of the cell biology and physiology of particular nAChR subtypes.

Midbrain DA neurons and other cells in local and long-range circuits that directly synapse onto DA neurons express distinct nAChR subtypes on their cell surface. GABAergic cells in the substantia nigra pars reticulata and the ventral tegmental area (VTA) express $\alpha 4\beta 2^*$ (* indicates that other nAChR subunits may be present) nAChRs receptors with at least two sensitivities to ACh and nicotine (Nashmi et al., 2007; Xiao et al., 2009). Midbrain DA neurons express as many as seven distinct nAChR subtypes or stoichiometric variants: $(\alpha 4)_3(\beta 2)_2$, $(\alpha 4)_2(\beta 2)_3$, $\alpha 4\beta 2\alpha 5$, $\alpha 6\beta 2$, $\alpha 6\beta 2\beta 3$, $\alpha 6\alpha 4\beta 2$, and $\alpha 6\alpha 4\beta 2\beta 3$ (Gotti et al., 2005; Salminen et al., 2007). $\beta 2$ subunits are strictly required for nAChR function in midbrain DA neurons (Picciotto et al., 1998; Maskos et al., 2005); $\alpha 4$ subunits are expressed in nearly all DA neurons, and loss of $\alpha 4$ subunits eliminates 80% of surface nAChRs in these cells (Azam et al., 2002; Marubio et al., 2003; Nashmi et al., 2007; Xiao et al., 2009). Functional $\alpha 6^*$ nAChRs are highly and selectively expressed in DA neurons (Drenan et al., 2008b), where they assemble with $\beta 2$, and often, $\beta 3$ and/or $\alpha 4$ subunits (Champiaux et al., 2002, 2003; Cui et al., 2003; Drenan et al., 2008a).

Previous studies indicate that $\alpha 6\alpha 4\beta 2\beta 3$ nAChR pentamers are important regulators of DA release. For instance, studies on

Received April 14, 2010; revised June 14, 2010; accepted June 16, 2010.

This work was supported by grants from the National Institutes of Health (NIH) (DA17279 and AG033954 to H.A.L.; DA19375 to H.A.L. and M.J.M.; DA12242, DA015663, and DA03194 to M.J.M.; MH53631 and GM48677 to J.M. McIntosh), the Moore Foundation, the Croll Research Foundation (to J. M. Miwa), and the California Tobacco Related Disease Research Program (TRDRP; 12RT-0245 to H.A.L.). A.D.S. is funded by the Broad Fellow Program in Brain Circuitry at Caltech and an Ellison Medical Foundation New Scholar in Aging award. R.M.D. was supported by postdoctoral fellowships from TRDRP (15FT-0030) and NIH (DA021492 and NS007251). We thank members of the Lester laboratory for helpful discussion. Thanks to P. Deshpande, M. Liu, C. Xiao, E. Mackey, G. Akopian, S. Benazouz, L. Sandoval, C. Baddick, and C. Wageman. We thank Oliver King and Cynthia Hsu for writing Matlab programs for home cage behavior data analysis.

Correspondence should be addressed to Henry A. Lester, California Institute of Technology, Division of Biology, M/C 156-29, 1200 East California Boulevard, Pasadena, CA 91125. E-mail: lester@caltech.edu.

DOI:10.1523/JNEUROSCI.2056-10.2010

Copyright © 2010 the authors 0270-6474/10/309877-13\$15.00/0

nicotine-evoked DA release from striatal synaptosomes indicate that $\alpha 6\alpha 4\beta 2\beta 3$ nAChRs have the highest sensitivity to nicotine ($EC_{50} = 230$ nM) (Salminen et al., 2007). Because nicotine reaches a concentration of 100–500 nM in brain CSF during cigarette smoking, $\alpha 6\alpha 4\beta 2\beta 3$ nAChRs on DA neurons are most likely to respond. We recently constructed mice expressing gain-of-function $\alpha 6^{L9'S^*}$ receptors to amplify and isolate behavioral and physiological responses resultant from $\alpha 6^*$ nAChR activation (Drenan et al., 2008b). These mice exhibit marked locomotor hyperactivity due to enhanced sensitivity of DA neuron firing and/or release in response to low concentrations of nicotine or ACh. To further study the partially overlapping functions of $\alpha 6^*$, $\alpha 4^*$, and $\alpha 6\alpha 4^*$ nAChRs, we crossed $\alpha 4$ knock-out (KO) mice with $\alpha 6^{L9'S}$ mice. This strain of mice discriminates, for the first time *in vivo*, between $\alpha 6\alpha 4\beta 2^*$ and $\alpha 6(\text{non-}\alpha 4)\beta 2^*$ nAChRs. Here we describe experiments showing that $\alpha 4$ subunits are critical for $\alpha 6^*$ -mediated behavioral phenotypes. Furthermore, using electrochemical measurements, we show that DA release kinetics are significantly altered in $\alpha 6^{L9'S}$ mice, and that this alteration depends on $\alpha 6\alpha 4\beta 2^*$ nAChRs.

Materials and Methods

Mice. All experiments were conducted in accordance with the guidelines for care and use of animals provided by the Office of Laboratory Animal Welfare at the National Institutes of Health, and protocols were approved by the Institutional Animal Care and Use Committee at the California Institute of Technology or the University of Colorado at Boulder. Mice were kept on a standard 12/12 or 13/11 h light/dark cycle at 22°C and given food and water *ad libitum*. On postnatal day 21, mice were weaned and housed with same-sex littermates. At 21–28 d, tail biopsies were taken for genotype analysis by PCR. Tails were digested in 50 mM NaOH at 95°C for 45 min followed by neutralization with 0.5 M Tris-Cl, pH 5.5, and subsequent direct analysis by multiplex PCR. $\alpha 6^{L9'S}$ mice were generated as described previously (Drenan et al., 2008b) and were backcrossed to C57BL/6 six to eight times. All studies described here use “line 2” $\alpha 6^{L9'S}$ mice (Drenan et al., 2008b). $\alpha 4\text{KO}/\alpha 6^{L9'S}$ mice were generated by first crossing $\alpha 4\text{KO}$ (Ross et al., 2000) mice with $\alpha 6^{L9'S}$ mice to generate $\alpha 4^{+/-}/\alpha 6^{L9'S}$ mice, which were crossed again to $\alpha 4\text{KO}$ mice to produce $\alpha 4\text{KO}/\alpha 6^{L9'S}$ progeny. Mice of this genotype were continually backcrossed to $\alpha 4\text{KO}$, and the presence of the $\alpha 6^{L9'S}$ transgene and the $\alpha 4$ null mutation was independently confirmed for each mouse using PCR. $\alpha 4\text{KO}$ mice used in this study were littermates of $\alpha 4\text{KO}/\alpha 6^{L9'S}$ mice, and wild-type (WT) control mice were littermates of $\alpha 6^{L9'S}$ transgenic mice. All groups of mice in this study contained approximately equal numbers of males and females.

Mouse locomotor activity. Mice used to study locomotion were 8–16 weeks old at the beginning of an experiment. Backcrossing to C57BL/6 did not affect locomotor activity (data not shown). Horizontal locomotor activity was measured with an infrared photobeam activity cage system (San Diego Instruments). Ambulation events were recorded when two contiguous photobeams were broken in succession. Acute locomotor activity in response to nicotine was studied by recording ambulation events during four 15 s intervals per minute for a designated number of minutes. For most experiments, groups of eight mice were placed in activity cages (18 × 28 cm) and their baseline level of activity was recorded for 8 min. Mice were removed from their cage, injected (100 μ l per 25 g of body mass), and returned to the cage within 15 s. For generation of locomotor activity dose–response relationships, a group of mice was administered saline and, after 5–8 d off, each successive dose of drug. For 48 h home cage monitoring, mice were isolated in their own cage and habituated to the test room and cage for 24 h. Following this, locomotor activity was recorded in 15 min intervals for 48 h.

Automated mouse behavior analysis. Video-based software analysis of home cage behavior was conducted as described previously (Steele et al., 2007). Mice that were normally group housed were singly caged and habituated to the video recording room and a fresh home cage for 24 h before recording. The video recording began the following day (2 h be-

fore the dark phase) and continued for 23.5–24.0 h, using dim red lights for recording during the dark phase. The videos were analyzed using the definitions and settings described (Steele et al., 2007) using HomeCageScan 3.0 software (Clever Sys) (see Fig. 2A). The visualization in Figure 2A was created in Matlab. The sample sizes were as follows: WT, $n = 8$; $\alpha 6^{L9'S}$, $n = 21$; $\alpha 4\text{KO}$, $n = 14$; $\alpha 4\text{KO}/\alpha 6^{L9'S}$, $n = 13$.

Fast scan cyclic voltammetry in striatal slices. Mice (postnatal day 60–90) were anesthetized with sodium pentobarbital (40 mg/kg, i.p.) followed by cardiac perfusion with oxygenated (95% O₂/5% CO₂) ice-cold glycerol-based artificial CSF (gACSF) containing 252 mM glycerol, 1.6 mM KCl, 1.2 mM NaH₂PO₄, 1.2 mM MgCl₂, 2.4 mM CaCl₂, 18 mM NaHCO₃, and 11 mM glucose. Following perfusion, brains were removed and retained in gACSF (0–4°C). Coronal slices (300 μ m) were cut with a microslicer (DTK-1000; Ted Pella) at a frequency setting of 9 and a speed setting of 3.25. Brain slices were allowed to recover for at least 1 h at 32°C in regular, oxygenated artificial CSF (ACSF) containing 126 mM NaCl, 1.6 mM KCl, 1.2 mM NaH₂PO₄, 1.2 mM MgCl₂, 2.4 mM CaCl₂, 18 mM NaHCO₃, and 11 mM glucose. Coordinates for recordings in the caudate/putamen (CPU) were within the following range: (0.0 to +1.0 mm from bregma, –3.0 to –4.0 mm from the surface, and –1.0 to –3.0 from the midline).

Carbon fiber (7 μ m, unsize; Goodfellow) electrodes were fabricated at Caltech using anodic electrodeposition of paint (Schulte and Chow, 1996; Akopian et al., 2008). Voltammetry data were acquired with a Multiclamp 700A amplifier (Molecular Devices). The command microelectrode potential was –400 mV (against a Ag/AgCl reference electrode), and the potential was scanned from –400 mV to +1000 mV to –400 mV at a rate of 300 mV/ms; ramp frequency was 10 Hz. Dopamine release was elicited by stimulating DA fibers with a bipolar stimulating electrode (FHC), placed 200–300 μ m from the recording site. The stimulus (0.65 mA, 250 μ s) elicited maximal release, and stimulus trains were generated with an Anapulse Stimulator (World Precision Instruments). Eliciting maximal release reduced variability across experiments by maximizing the number of fibers carrying action potentials in the vicinity of the recording site (Cragg, 2003). When tested, all DA release responses were blocked by tetrodotoxin (data not shown). Pulse trains were delivered at 100 Hz, similar to the maximal firing rate of DA neurons observed in mammals (Rice and Cragg, 2004; Zhang and Sulzer, 2004). A fresh carbon fiber surface was exposed each recording day. Voltammetry protocols were initially run for ~30 min to allow the background currents to settle to an optimal waveform, and were run continually throughout the day when stimulation protocols were not run. Background currents were subtracted from signals acquired during striatal stimulation to isolate transient neurotransmitter release events. DA release recovered fully within 2 min after stimulus trains, and trains were typically delivered at 3 min intervals. Each day, electrodes were calibrated against DA standards in solution (2.5 and 5.0 μ M DA). Absolute DA concentrations for release responses in slices were determined using these standards. We hold to convention and indicate pulse trains by 1p, 2p, etc.; individual pulses within a train are indicated as p1, p2, etc. For paired-pulse experiments, responses to 1p and 2p (100 Hz) stimulation were recorded. Release due to the second of a pair of pulses (p2) was isolated by subtracting the response to a single pulse (p1, i.e., 1p) from the response to a 2p train.

Dopamine release from striatal synaptosomes. After a mouse was killed by cervical dislocation, its brain was removed and placed immediately on an ice-cold platform and brain regions were dissected. Tissues from each mouse were homogenized in 0.5 ml of ice-cold 0.32 M sucrose buffered with 5 mM HEPES, pH 7.5. A crude synaptosomal pellet was prepared by centrifugation at 12,000 × g for 20 min. The pellets were resuspended in “uptake buffer”: 128 mM NaCl, 2.4 mM KCl, 3.2 mM CaCl₂, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 25 mM HEPES, 10 mM glucose, 1 mM ascorbic acid, and 10 μ M pargyline at pH 7.5. Synaptosomes were incubated at 37°C in uptake buffer for 10 min before addition of 100 nM [³H]-dopamine (1 μ Ci per 0.2 ml of synaptosomes), and the suspension was incubated for an additional 5 min.

All experiments were conducted at room temperature using methods described previously (Nashmi et al., 2007; Salminen et al., 2007) with modifications for collection into 96-well plates. In brief, aliquots of synaptosomes (80 μ l) were distributed onto filters and perfused with buffer

[uptake buffer containing 0.1% bovine serum albumin (BSA), 1 μM atropine, and 1 μM nomifensine at 0.7 ml/min for 10 min, or buffer for 5 min followed by buffer with 50 nM αCtXMII]. Aliquots of synaptosomes were then exposed to nicotine in buffer for 20 s to stimulate release of [^3H]dopamine followed by buffer. Fractions (~ 0.1 ml) were collected for 4 min into 96-well plates every 10 s starting from 1 min before stimulation, using a Gilson FC204 fraction collector with a multicolumn adapter (Gilson). Radioactivity was determined by scintillation counting using a 1450 MicroBeta Trilux scintillation counter (PerkinElmer Life Sciences) after addition of 0.15 ml of Optiphase 'SuperMix' scintillation cocktail. Instrument efficiency was 40%.

Data were analyzed using SigmaPlot 5.0 for DOS. Perfusion data were plotted as counts per minute (cpm) versus fraction number. Fractions collected before and after the peak were used to calculate baseline as a single-exponential decay. The calculated baseline was subtracted from the experimental data. Fractions that exceeded baseline by 10% or more were summed to give total released cpm and then normalized to baseline to give units of release [(cpm – baseline)/baseline] (Salminen et al., 2007).

Dopamine uptake. Synaptosomes were prepared as described for DA release assays. Synaptosomes were suspended in uptake buffer (described above) at a concentration of 8 ml per mouse for dorsal striatum (ST) and 4 ml per mouse for olfactory tubercle (OT). For each well, synaptosomes (25 μl) were incubated in uptake buffer (final volume 100 μl) with either 0.05 μM or 1 μM [^3H]dopamine at 22°C for 5 min. Nomifensine (100 μM) was used for blank determination. The reaction was terminated by filtration onto a two layer filter consisting of one sheet of GFA/E glass fiber filter (Gelman Sciences) one sheet of GF/B glass fiber filter (Micro Filtration Systems) both soaked in uptake buffer. Samples were washed with cold uptake buffer four times. Radioactivity was measured using a Wallac 1450 MicroBeta scintillation counter (PerkinElmer Life and Analytical Sciences) after addition of 50 μl of Optiphase Supermix scintillation cocktail (PerkinElmer Life Sciences) to each well of a 96-well counting plate. Previously, we have determined K_M concentration of DA for uptake into striatal synaptosomes of C57BL/6 mice to be 0.080 ± 0.003 μM (data not shown).

Ligand binding. K_d values for each radioligand were determined by saturation binding to membranes prepared from C57BL/6 mice (data not shown). All protein determinations were done by the Lowry method with bovine serum albumin (BSA) as standard.

Previously published methods (Marks et al., 2006; Brown et al., 2007) were followed to measure high-affinity [^{125}I]epibatidine (2200 Ci/mmol) binding to membrane preparations using a 96-well plate format. Briefly, membranes treated with phenylmethylsulfonyl fluoride (1 mM) were incubated with [^{125}I]epibatidine (200 pM; $K_d \sim 40$ pM) in binding buffer [30 μl volume including: 144 mM NaCl, 1.5 mM KCl, 2 mM CaCl_2 , 1 mM MgSO_4 , 20 mM HEPES, pH 7.5 with BSA (0.1% w/v), 5 mM EDTA, 5 mM EGTA, 10 $\mu\text{g/ml}$ each aprotinin, leupeptin trifluoroacetate, and pepstatin A]. To some samples, αCtXMII (100 nM) was added to measure αCtXMII -sensitive epibatidine binding by subtraction from total binding [the $\alpha 6\beta 2^*$ -nAChR population (see Salminen et al., 2005)]. Nonspecific binding was determined by including L-nicotine (1 mM). Plates were incubated for 2 h at 22°C.

The D_1/D_5 dopamine receptors were measured by membrane binding of [^3H]SCH23390 ([N-methyl- ^3H]; 70–87 Ci/mmol). Membrane preparations were incubated in binding buffer (30 μl volume including the following: 144 mM NaCl, 1.5 mM KCl, 2 mM CaCl_2 , 1 mM MgSO_4 , 20 mM HEPES, pH 7.5) with [^3H]SCH23390 used at 1.7 nM ($K_d \sim 0.1$ nM), with 0.5 μM mianserin added to block binding to 5-HT $_2$ receptors, and 10 mM flupenthixol added for blank determination. Samples were incubated for 60 min at 22°C. The D_2/D_3 dopamine receptors were measured with [^3H]raclopride ([methoxy- ^3H]; 60–87 Ci/mmol). The procedure was the same as for D_1/D_5 sites using [^3H]raclopride at 17 nM, ($K_d \sim 2$ nM) with 10 μM sulpiride added for blank determination. Incubation was for 60 min at 22°C. The dopamine transporter (DAT) was measured by binding of [^3H]mazindol (15–30 Ci/mmol) at 200 nM ($K_d \sim 25$ nM) with addition of 1 μM fluoxetine to block the serotonin transporter and 100 nM desipramine to block norepinephrine transporters. Blanks were de-

termined using 100 μM nomifensine. Samples were incubated for 90 min at 22°C followed by 30 min at 4°C.

For all membrane binding assays, reactions were terminated by filtration of samples at 4°C onto a two layer filter consisting of one sheet of GFA/E glass fiber filter (Gelman Sciences) and one sheet of GF/B glass fiber filter (Micro Filtration Systems) both treated with 0.5% polyethylenimine using an Inotech Cell Harvester (Inotech). Samples were subsequently washed six times with ice-cold binding buffer. Radioactivity was measured using a Wallac 1450 MicroBeta scintillation counter (PerkinElmer Life and Analytical Sciences) after addition of 50 μl of Optiphase Supermix scintillation cocktail (PerkinElmer Life Sciences) to each well of a 96-well counting plate.

Statistical analysis. Home cage locomotor ambulation data were analyzed for significance with a one-way ANOVA with Tukey *post hoc* analysis (Drenan et al., 2008b). For automated mouse behavior analysis (AMBA) behavioral experiments, data were analyzed for significance with a two-tailed Wilcoxon rank-sum test (nonparametric) (Steele et al., 2007). nAChR ligand binding, DA receptor ligand binding, DAT ligand binding, and DAT uptake data were analyzed for significance with a *t* test within a brain region (ST or OT) and within a genetic background (WT or $\alpha 4\text{KO}$). Synaptosomal DA release curves were fit to the Michaelis–Menten equation (Hill coefficient = 1), and R_{max} and EC_{50} values were evaluated for statistical significance using a *t* test within a brain region (ST or OT) and within a genetic background (WT or $\alpha 4\text{KO}$). Voltammetry data were evaluated for significance with a *t* test within a genotype, where 1p and 4p data were compared.

Materials. All radioactive compounds were obtained from PerkinElmer. αCtXMII was synthesized as previously described (Cartier et al., 1996). Ultra centrifugation grade sucrose was obtained from Fisher Chemicals. Sigma-Aldrich was the source for the following compounds: ascorbic acid, atropine sulfate, bovine serum albumin (BSA), (–)-nicotine tartrate, nomifensine, cytosine, and pargyline. Optiphase 'SuperMix' scintillation fluid was from PerkinElmer Life Sciences.

Results

$\alpha 6\alpha 4^*$ nAChR-mediated locomotion and behavioral analysis

$\alpha 6^{L9'S}$ BAC transgenic mice use the full $\alpha 6$ promoter to drive the expression of a leucine 9' to serine mutation in the ion channel pore lining transmembrane (TM2) domain of the $\alpha 6$ nAChR subunit, rendering them hypersensitive to agonist (Drenan et al., 2008b). $\alpha 6^{L9'S}$ mice show robust locomotor hyperactivity in the home cage and in response to systemic nicotine injections (Drenan et al., 2008b), thus providing a system with a broad dynamic range to study further genetic manipulations. We crossed *Chrna4* homozygous null mutant mice ($\alpha 4\text{KO}$ mice) with $\alpha 6^{L9'S}$ mice, then bred the resultant $\alpha 4^{+/-}/\alpha 6^{L9'S}$ mice with $\alpha 4\text{KO}$ mice again to inactivate both copies of *Chrna4*. This manipulation removes several nAChR subtypes: $\alpha 4\beta 2$ (both high-sensitivity and low-sensitivity components), $\alpha 4\beta 2\alpha 5$, $\alpha 6\alpha 4\beta 2$, and $\alpha 6\alpha 4\beta 2\beta 3$ receptors, leaving only $\alpha 6\beta 2\beta 3$ and $\alpha 6\beta 2$ nAChRs (a minority, lower-sensitivity subtype) (Fig. 1A). These mice ($\alpha 4\text{KO}/\alpha 6^{L9'S}$) are viable, fertile, and exhibit qualitatively normal social interactions compared to both $\alpha 6^{L9'S}$ mice and $\alpha 4\text{KO}$ mice (data not shown). We measured home cage activity over 48 h for WT, $\alpha 6^{L9'S}$, $\alpha 4\text{KO}$, and $\alpha 4\text{KO}/\alpha 6^{L9'S}$ mice. As previously reported, $\alpha 6^{L9'S}$ mice exhibit substantial locomotor hyperactivity relative to WT mice during the dark phase (their active period) (Fig. 1B), and this difference was highly significant when total ambulations were quantified (lights off #1: WT, 5860 ± 765 ambulations/15 min; $\alpha 6^{L9'S}$, $34,887 \pm 6800$ ambulations/15 min; $p < 0.01$) (lights on: WT, 2005 ± 301 ambulations/15 min; $\alpha 6^{L9'S}$, 4238 ± 723 ambulations/15 min; $p > 0.05$) (lights off #2: WT, 5030 ± 616 ; $\alpha 6^{L9'S}$, $35,491 \pm 6869$; $p < 0.01$) (Fig. 1C). WT and $\alpha 4\text{KO}$ mice had normal home cage locomotor activity (Fig. 1B, C). Surprisingly, the home cage hyperactivity in $\alpha 6^{L9'S}$ mice was completely abolished in $\alpha 4\text{KO}/\alpha 6^{L9'S}$ animals

(lights off #1: $\alpha 4$ KO, 6057 ± 1392 ambulations/15 min; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 7821 ± 2225 ambulations/15 min; $p > 0.05$) (lights on: $\alpha 4$ KO, 2174 ± 354 ambulations/15 min; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 2056 ± 504 ambulations/15 min; $p > 0.05$) (lights off #2: $\alpha 4$ KO, 6328 ± 2014 ; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 7021 ± 2187 ; $p > 0.05$ (Fig. 1B,C), revealing that $\alpha 4$ subunits are required for the pronounced phenotype seen in $\alpha 6^{L9'S}$ mice.

$\alpha 6^{L9'S}$ mice are hypersensitive to nicotine, demonstrating locomotor activation (rather than locomotor suppression seen in WT mice) in response to low doses of nicotine and other nAChR ligands (Drenan et al., 2008b). In response to 0.2 mg/kg nicotine, $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice showed only partial locomotor activation over a 30 min time course when compared to the response seen in $\alpha 6^{L9'S}$ mice (peak locomotor response: $\alpha 6^{L9'S}$, 93 ± 14 ambulations/min; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 53 ± 4 ambulations/min) (Fig. 1D). To further study this effect, we constructed nicotine dose–response relations for WT, $\alpha 6^{L9'S}$, $\alpha 4$ KO, and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice. As seen previously, $\alpha 6^{L9'S}$ mice demonstrated locomotor activation across a range of nicotine concentrations that do not significantly affect WT mice (Fig. 1E). WT mice responded only to the highest tested dose (1.5 mg/kg) with suppression of locomotor activity, and locomotor activity of $\alpha 4$ KO animals was not altered in response to the concentrations tested (Fig. 1E), consistent with previous results (Tapper et al., 2007). The potency and efficacy of nicotine were consistently reduced in $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice compared to $\alpha 6^{L9'S}$ mice (Fig. 1E), suggesting the emergence of alterations in the sensitivity and/or number of $\alpha 6^*$ receptors when $\alpha 4$ subunits are removed.

To better understand the altered behavior in $\alpha 6^{L9'S}$ mice and the effect of $\alpha 4$ subunit removal, we extended the behavioral analysis of these mice using AMBA with a video-based behavioral recognition system. This system has previously been validated on several mutant mouse strains that exhibit altered behavior, including mouse models of Huntington's disease and prion diseases (Steele et al., 2007, 2008). Mice are singly housed in their standard cage while the AMBA software analyzes a video feed of the mouse's activity (Fig. 2A). To verify that AMBA analyses correspond with the beam-break method (Fig. 1), we analyzed distance traveled with AMBA. Consistent with the beam-break data (Fig. 1) and our previous work (Drenan et al., 2008b), there was a dramatic and statistically significant increase in the mean distance traveled in $\alpha 6^{L9'S}$ mice compared to WT littermates (WT, 281 ± 28 m/24 h; $\alpha 6^{L9'S}$, 2469 ± 535 m/24 h; $p < 0.05$) (Fig. 2B). In contrast, we observed no statistically significant increase in distance traveled when $\alpha 4$ KO mice were compared to $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice, al-




Figure 1. Hyperactivity in $\alpha 6^{L9'S}$ mice requires $\alpha 4$ nAChR subunits. **A**, Probable receptor subtypes expressed in DA neurons of mice examined in this study. The three main nicotinic receptor subtypes expressed in DA neurons of WT mice, $\alpha 6\alpha 4\beta 2\beta 3^*$, $\alpha 6\beta 2\beta 3^*$, and $\alpha 4\beta 2^*$, are shown. $\alpha 6^{L9'S}$ mice express $\alpha 6\alpha 4\beta 2\beta 3^*$ and/or $\alpha 6\beta 2\beta 3^*$ nAChRs with augmented sensitivity relative to the other subtypes, and $\alpha 4$ KO and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice express only $\alpha 6\beta 2\beta 3^*$ and/or $\alpha 6\beta 2^*$ nAChRs. **B, C**, $\alpha 6^{L9'S}$ mice, but not $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice, are hyperactive in their home cage. Horizontal locomotor activity of mice ($\alpha 6^{L9'S}$ and WT littermates; $\alpha 4$ KO/ $\alpha 6^{L9'S}$ and $\alpha 4$ KO littermates) in their home cage environment was recorded over 48 h. Raw locomotor activity data (number of ambulations/15 min period) are reported (**B**). Total locomotor activity from “lights on” and “lights off” periods indicated in **B** are shown in **C** for all genotypes. **D**, Nicotine-mediated locomotor activation in $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice is reduced relative to $\alpha 6^{L9'S}$ mice. After 8 min of baseline locomotor activity, mice ($\alpha 6^{L9'S}$ and $\alpha 4$ KO/ $\alpha 6^{L9'S}$) were injected with 0.2 mg/kg nicotine (i.p.). Locomotor activity was recorded for an additional 30 min after injection. Raw locomotor activity data (number of ambulations/min) are reported. **E**, Dose–response relationship for nicotine-stimulated locomotor activity in WT, $\alpha 6^{L9'S}$, $\alpha 4$ KO, and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice. Mice were administered nicotine at the indicated dose, and total locomotor activity was measured as in **D**. Locomotor activity for each mouse was normalized to a saline control injection for the same mouse. Data are expressed as the percentage of the response to saline (set to 100%). Data are expressed as mean \pm SEM. The number of mice for home cage locomotor activity experiments was as follows: WT, $n = 7$; $\alpha 6^{L9'S}$, $n = 16$; $\alpha 4$ KO, $n = 8$; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, $n = 8$. The number of mice for nicotine-stimulated locomotor activity experiments was as follows: WT, $n = 8$; $\alpha 6^{L9'S}$, $n = 8$; $\alpha 4$ KO, $n = 8$; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, $n = 8$. All statistically significant comparisons are indicated. ** $p < 0.01$.

though there was a trend toward increased distance with the presence of the $\alpha 6^{L9'S}$ BAC transgene ($\alpha 4$ KO, 344 ± 62 m/24 h; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 1203 ± 568 m/24 h; $p > 0.05$) (Fig. 2B). It is not clear why the $\alpha 6^{L9'S}$ behavioral hyperactivity phenotype is highly variable and only partially penetrant (Fig. 2B), but genetic mosaicism or epigenetic changes are possible explanations.

We used the power of AMBA to discriminate among several specific behaviors in the genotypes under investigation. Specific behaviors were extracted by the HomeCageScan 3.0 software and expressed as a percentage of total time recorded (percentage of total frames). Compared to WT littermates, $\alpha 6^{L9'S}$ mice exhibited robust differences in median values for a variety of behaviors. In particular, $\alpha 6^{L9'S}$ mice showed the greatest difference from WT control mice in behaviors of activity or ambulatory movement, including “jump,” “walk,” “stretch,” “turn,” and “rear”




Figure 2. AMBA reveals specific behaviors affected by augmented DA release. **A**, HomeCageScan system for recording and analyzing mouse behavior. Mice were singly housed in and habituated to a standard cage for video recording (top panel), and HomeCageScan software (bottom panel) analyzed mouse behavior in real time. **B**, $\alpha 6^{L9'S}$ mice traveled greater distance than WT controls. Distance traveled over 24 h was calculated and plotted for each WT, $\alpha 6^{L9'S}$, $\alpha 4$ KO, and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mouse. **C**, $\alpha 4$ subunits are required for hypersensitive $\alpha 6^*$ nAChRs to alter mouse behavior. In each of the 4 mouse genotypes indicated, AMBA was used to calculate the percentage of total time that each mouse spent exhibiting each of 17 specific behaviors. Median values for each behavior were compared between genotypes ($\alpha 6^{L9'S}$ vs WT; $\alpha 4$ KO/ $\alpha 6^{L9'S}$ vs $\alpha 4$ KO), and the fold change in median for each behavior of either $\alpha 6^{L9'S}$ or $\alpha 4$ KO/ $\alpha 6^{L9'S}$ over its respective control group (WT or $\alpha 4$ KO) is expressed via a heat map with yellow indicating an increase in median value and blue indicating a decrease in median value. **D**, **E**, Behavioral differences between $\alpha 6^{L9'S}$ and WT control mice largely require $\alpha 4$ nAChR subunits. For either $\alpha 6^{L9'S}$ versus WT (**D**) or $\alpha 4$ KO/ $\alpha 6^{L9'S}$ versus $\alpha 4$ KO (**E**), the percentage of total time during 24 h that mice spent exhibiting each indicated behavior is plotted. Two y -axes are used because several behaviors occupy a large fraction of total time and all behaviors could not be displayed effectively on a single y -axis. Data are expressed as mean \pm SEM. The number of mice in each group was as follows: WT, $n = 8$; $\alpha 6^{L9'S}$, $n = 21$; $\alpha 4$ KO, $n = 13$; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, $n = 14$. All statistically significant comparisons are indicated. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

(Fig. 2C). We also noted a large increase in the percentage of time $\alpha 6^{L9'S}$ mice exhibited “high-velocity,” erratic behaviors that are poorly resolved at the video camera’s frame rate and by the AMBA algorithms (Steele et al., 2007). As expected, the $\alpha 6^{L9'S}$ mice displayed a corresponding decrease in several relatively inactive behaviors, such as “pause,” “hang vertical,” “hang cuddled,” and “drink” (Fig. 2C). For $\alpha 6^{L9'S}$ mice relative to WT littermates, we found a statistically significant difference for nine behaviors when we compared the percentage of total time spent exhibiting each behavior. $\alpha 6^{L9'S}$ mice spent less total time drinking, hanging cuddled, pausing, and grooming (Fig. 2D). In contrast, $\alpha 6^{L9'S}$ mice spent a greater percentage of total time jumping, turning, rearing, and walking, as well as more time exhibiting “high-velocity” behaviors (Fig. 2D). There was also a trend toward reduced eating and reduced resting in $\alpha 6^{L9'S}$ mice compared to WT controls (Fig. 2D).

To study the effect of the $\alpha 6^{L9'S}$ mutation in the context of a *Chrn4* null mutant background, and to better understand the locomotor activity change that we noted in Figure 1A, we re-

corded and analyzed the detailed home cage behavior of $\alpha 4$ KO and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice. In contrast to the $\alpha 6^{L9'S}$ versus WT littermate comparison, we noticed only modest differences in the median value for the behaviors in AMBA for $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice compared to $\alpha 4$ KO controls (Fig. 2C). Furthermore, differences in eight of the nine behaviors that were statistically significant in $\alpha 6^{L9'S}$ versus WT were no longer significant in $\alpha 4$ KO/ $\alpha 6^{L9'S}$ versus $\alpha 4$ KO. Only rearing remained significantly different between the latter two genotypes (Fig. 2E). In summary, these behavioral results show for the first time the importance of $\alpha 4$ subunits in $\alpha 6^*$ nAChR function *in vivo*.

Augmented DA release in $\alpha 6^{L9'S}$ mice requires $\alpha 4$ subunits

Locomotor hyperactivity is reminiscent of imbalances in striatal DA reported for other genetic models exhibiting abnormal DA transmission (Giros et al., 1996; Zhuang et al., 2001). $\alpha 6^*$ nAChRs are selectively expressed in SNc and VTA DA neurons cell bodies and their terminal fields, most notably dorsal and ventral striatum (Champtiaux et al., 2002, 2003). Although the

primary effect of the L9'S mutation is to augment the function of $\alpha 6^*$ receptors, it is possible that the behavioral differences seen between WT and $\alpha 6^{L9'S}$ or between $\alpha 4$ KO and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ are due to differences in receptor expression. To address this, we quantified the number of $\alpha 4\beta 2^*$ and $\alpha 6\beta 2^*$ binding sites using [125 I]epibatidine in striatum and olfactory tubercle of these mouse lines. We separately dissected the ST and the OT, thus roughly separating the nigrostriatal and mesolimbic DA pathways (Ikemoto, 2007). We used α CtxMII to separate $\alpha 4\beta 2^*$ (MII-resistant) from $\alpha 6\beta 2^*$ (MII-sensitive), the two predominant subtypes in this preparation. There was no significant difference in the number (Fig. 3A,D) (ST: WT, 14.2 ± 1.0 fmol/mg protein; $\alpha 6^{L9'S}$, 15.1 ± 2.4 fmol/mg protein; $p > 0.05$) (OT: WT, 10.6 ± 1.0 fmol/mg protein; $\alpha 6^{L9'S}$, 9.0 ± 0.9 fmol/mg protein; $p > 0.05$) or the percentage (Fig. 3B,E) (ST: WT, $23.7 \pm 1.2\%$ MII-sens; $\alpha 6^{L9'S}$, $24.0 \pm 3.7\%$ MII-sens; $p > 0.05$) (OT: WT, $24.4 \pm 2.0\%$ MII-sens; $\alpha 6^{L9'S}$, $19.5 \pm 1.7\%$ MII-sens; $p > 0.05$) of $\alpha 6\beta 2^*$ binding sites between WT and $\alpha 6^{L9'S}$ mice, either in ST or OT, which is consistent with our previous analysis (Drenan et al., 2008b). In OT, we noticed a small but significant increase in MII-resistant ($\alpha 4\beta 2^*$) receptors in $\alpha 6^{L9'S}$ mice (OT: WT, 32.6 ± 1.3 fmol/mg protein; $\alpha 6^{L9'S}$, 37.1 ± 0.5 fmol/mg protein; $p < 0.01$) (Fig. 3F), but no change in ST (ST: WT, 45.5 ± 1.2 fmol/mg protein; $\alpha 6^{L9'S}$, 47.7 ± 2.6 fmol/mg protein; $p > 0.05$) (Fig. 3C). In $\alpha 4$ KO mice, there was a 50–60% reduction in $\alpha 6\beta 2^*$ receptor numbers in both brain areas (Fig. 3A,D), consistent with previous studies (Salminen et al., 2005, 2007). This was accompanied by a consequent increase in the percentage of MII-sensitive epibatidine binding in mice lacking $\alpha 4$ subunits compared to WT and $\alpha 6^{L9'S}$ mice (Fig. 3B,E). We noted trace MII-resistant epibatidine binding in $\alpha 4$ KO and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ ST and OT (Fig. 3C,F), which may represent a minor population of $\beta 4^*$ nAChRs (Klink et al., 2001; Azam et al., 2002; Gahring et al., 2004). In both ST (Fig. 3A) and OT (Fig. 3D), there was a further reduction in $\alpha 6\beta 2^*$ receptors in $\alpha 4$ KO/ $\alpha 6^{L9'S}$ tissue compared to $\alpha 4$ KO (ST: $\alpha 4$ KO, 6.0 ± 0.5 fmol/mg protein; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 2.9 ± 0.4 fmol/mg protein; $p < 0.001$) (OT: $\alpha 4$ KO, 2.9 ± 0.5 fmol/mg protein; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 1.5 ± 0.2 fmol/mg protein; $p < 0.05$), but this did not correspond to any significance difference in the percentage of MII-sensitive binding sites in either of these brain areas (ST: $\alpha 4$ KO, $61.1 \pm 1.5\%$ MII-sens; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, $57.0 \pm 3.1\%$ MII-sens; $p > 0.05$) (OT: $\alpha 4$ KO, $41.8 \pm 4.6\%$ MII-sens; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, $34.9 \pm 4.0\%$ MII-sens; $p > 0.05$) (Fig. 3B,E). There was a small difference in MII-resistant binding in ST for $\alpha 4$ KO/ $\alpha 6^{L9'S}$ versus $\alpha 4$ KO mice (ST: $\alpha 4$ KO, 3.8 ± 0.3 fmol/mg protein; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 2.2 ± 0.3 fmol/mg protein; $p < 0.01$) (Fig. 3C), but not in OT (OT: $\alpha 4$ KO, 4.1 ± 0.6 fmol/mg protein; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, 2.8 ± 0.2 fmol/mg protein; $p > 0.05$) (Fig. 3F). Thus, receptor expression may account for a fraction of the effect




Figure 3. Quantitative analysis of $\alpha 6\beta 2^*$ and $\alpha 4\beta 2^*$ receptor levels in ST and OT. **A–C**, α CtxMII (50 nM) inhibition of [125 I]epibatidine binding separates $\alpha 6\beta 2^*$ and $\alpha 4\beta 2^*$ subtypes in ST of WT, $\alpha 6^{L9'S}$, $\alpha 4$ KO, and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice. Membrane preparations from ST of the indicated mice were incubated with [125 I]epibatidine in the presence and absence of competing, unlabeled α CtxMII. Raw binding values (**C**) for MII-resistant (mainly $\alpha 4\beta 2^*$) and MII-sensitive (mainly $\alpha 6\beta 2^*$) receptors (**A**), as well as percentage of MII-sensitive receptors (**B**) are shown. **D–F**, $\alpha 6\beta 2^*$ and $\alpha 4\beta 2^*$ receptor analysis for OT was performed identical to ST (**A–C**). Data are expressed as mean \pm SEM. The number of mice in each group was as follows: WT, $n = 7$; $\alpha 6^{L9'S}$, $n = 7$; $\alpha 4$ KO, $n = 6$; $\alpha 4$ KO/ $\alpha 6^{L9'S}$, $n = 5$. All statistically significant comparisons are indicated. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

seen in behavioral assays comparing $\alpha 4$ KO versus $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice, but not WT versus $\alpha 6^{L9'S}$ mice.

Functional aspects of presynaptic $\alpha 4^*$ and $\alpha 6^*$ nAChRs are effectively studied using agonist-evoked DA release from striatal synaptosomes (Grady et al., 2002). To study native nAChRs on DA terminals, we prepared synaptosomes from WT, $\alpha 6^{L9'S}$, $\alpha 4$ KO, and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ mice and measured nicotine-stimulated DA release. To separate responses dependent on $\alpha 6$ -containing from $\alpha 4$ (non- $\alpha 6$)-containing nAChRs, we blocked $\alpha 6^*$ nAChRs with α CtxMII as described previously (Salminen et al., 2004, 2007). In measurements on OT tissue (Fig. 4A), we noted a significant increase in R_{max} and a substantial reduction in EC_{50} at $\alpha 6^*$ OT nAChRs (Fig. 4B) comparing WT and $\alpha 6^{L9'S}$ mice (WT: $R_{max} = 4.6 \pm 0.3$ units, $EC_{50} = 0.075 \pm 0.025 \mu M$; $\alpha 6^{L9'S}$: $R_{max} = 14.7 \pm 0.7$ units, $EC_{50} = 0.015 \pm 0.004 \mu M$; R_{max} : $p < 0.001$; EC_{50} : $p < 0.05$) (Fig. 4G,H), consistent with previous results (Drenan et al., 2008b). We noted a corresponding decrease in R_{max} at (non- $\alpha 6$) $\alpha 4\beta 2^*$ nAChRs (Fig. 4C) in $\alpha 6^{L9'S}$ OT (WT: $R_{max} = 14.5 \pm 0.5$ units; $\alpha 6^{L9'S}$: $R_{max} = 7.4 \pm 0.4$ units; $p < 0.001$) (Fig. 4G), but also saw a minor, yet significant decrease in EC_{50} at these receptors as well (WT: $EC_{50} = 0.53 \pm 0.09 \mu M$; $\alpha 6^{L9'S}$: $EC_{50} = 0.24 \pm 0.06 \mu M$; $p < 0.05$) (Fig. 4H). Thus, the apparent increase in $\alpha 4\beta 2^*$ receptor (MII-resistant) numbers (Fig. 3F) in $\alpha 6^{L9'S}$ OT had no observed functional consequence. Results for this genotype comparison were very similar in ST (Fig. 4D) at $\alpha 6\beta 2^*$ (Fig. 4E) (WT: $R_{max} = 3.2 \pm 0.3$ units; $\alpha 6^{L9'S}$: $R_{max} = 6.6 \pm 0.5$ units; $p < 0.001$) (WT: $EC_{50} = 0.031 \pm 0.017 \mu M$; $\alpha 6^{L9'S}$: $EC_{50} = 0.016 \pm 0.006 \mu M$; $p > 0.05$) and (non- $\alpha 6$) $\alpha 4\beta 2^*$




Figure 4. Dopamine release from striatal presynaptic terminals is restored to WT levels in $\alpha 4$ KO/ $\alpha 6$ ^{L9'S} mice. **A–F**, Hypersensitive $\alpha 6^*$ nAChR-mediated DA release in $\alpha 6$ ^{L9'S} OT (**A–C**) and ST (**D–F**) is reversed by $\alpha 4$ nAChR subunit deletion. OT or ST from WT, $\alpha 6$ ^{L9'S}, $\alpha 4$ KO, and $\alpha 4$ KO/ $\alpha 6$ ^{L9'S} mice was dissected and synaptosomes were prepared. DA release was stimulated with a range of nicotine concentrations (1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 μ M, 10 μ M, 100 μ M, 300 μ M), and a concentration–response relation for each mouse line is shown for total release (**A**, **D**). To determine the relative contribution of $\alpha 6^*$ and non- $\alpha 6^*$ receptors, synaptosome samples were incubated with α CtxMII (50 nM). α CtxMII-sensitive ($\alpha 6^*$ dependent) release is shown in **B** and **E**, and $\alpha 6^*$ -independent release is shown in **C** and **F**. **G**, **H**, Quantification of DA release measured in **A–F** for WT, $\alpha 6$ ^{L9'S}, $\alpha 4$ KO, and $\alpha 4$ KO/ $\alpha 6$ ^{L9'S} mice in ST and OT. R_{max} (**G**) and EC_{50} (**H**) for α CtxMII-sensitive ($\alpha 6\beta 2^*$) and α CtxMII-resistant ($\alpha 4\beta 2^*$) DA release in ST and OT is shown. Data are expressed as mean \pm SEM. The number of mice in each group was as follows: WT, $n = 7$; $\alpha 6$ ^{L9'S}, $n = 7$; $\alpha 4$ KO, $n = 9$; $\alpha 4$ KO/ $\alpha 6$ ^{L9'S}, $n = 10$. All statistically significant comparisons are indicated. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

nAChRs (Fig. 4F) (WT: $R_{max} = 15.8 \pm 0.5$ units; $\alpha 6$ ^{L9'S}: $R_{max} = 7.8 \pm 0.2$ units; $p < 0.001$) (WT: $EC_{50} = 0.53 \pm 0.08$ μ M; $\alpha 6$ ^{L9'S}: $EC_{50} = 0.35 \pm 0.03$ μ M; $p > 0.05$) (Fig. 4D–H).

To study the effect of $\alpha 4$ subunit deletion on $\alpha 6^*$ nAChR function, we compared DA release results between $\alpha 4$ KO and $\alpha 4$ KO/ $\alpha 6$ ^{L9'S} mice. Previous results with $\alpha 4$ KO mice showed decreased R_{max} and increased EC_{50} compared to WT (Salminen et al., 2007), results that were replicated in this study. For $\alpha 6^*$ nAChRs in OT tissue (Fig. 4B), we noted only a slight increase in R_{max} for $\alpha 4$ KO/ $\alpha 6$ ^{L9'S} mice when compared to $\alpha 4$ KO mice ($\alpha 4$ KO: $R_{max} = 3.83 \pm 0.13$ units; $\alpha 4$ KO/ $\alpha 6$ ^{L9'S}: $R_{max} = 5.24 \pm 0.24$ units; $p < 0.001$) (Fig. 4G). There was a significant reduction in EC_{50} for $\alpha 4$ KO/ $\alpha 6$ ^{L9'S} compared to $\alpha 4$ KO ($\alpha 4$ KO: $EC_{50} = 0.97 \pm 0.15$ μ M; $\alpha 4$ KO/ $\alpha 6$ ^{L9'S}: $EC_{50} = 0.43 \pm 0.09$ μ M; $p < 0.01$) (Fig. 4H), but both values were at least one order of magnitude greater than for either WT or $\alpha 6$ ^{L9'S} mice. Results in ST (Fig. 4E) were similar for the $\alpha 4$ KO background ($\alpha 4$ KO: $R_{max} = 3.63 \pm 0.15$

units; $\alpha 4$ KO/ $\alpha 6$ ^{L9'S}: $R_{max} = 4.16 \pm 0.06$ units; $p < 0.01$) ($\alpha 4$ KO: $EC_{50} = 0.88 \pm 0.16$ μ M; $\alpha 4$ KO/ $\alpha 6$ ^{L9'S}: $EC_{50} = 0.25 \pm 0.02$ μ M; $p < 0.001$) (Fig. 4G,H). Thus, loss of $\alpha 4$ subunits from $\alpha 6^*$ nAChRs in $\alpha 6$ ^{L9'S} mice severely reduces the sensitivity of these receptors at DA nerve terminals despite the presence of a sensitizing serine residue at the M2 9' position. This decisively shows that without $\alpha 4$ subunits, DA neurons cannot augment their $\alpha 6\beta 2^*$ receptor sensitivity by producing increased numbers of receptors with one or more L9'S $\alpha 6$ subunit.

Burst firing selectively increases DA release in $\alpha 6$ ^{L9'S} dorsal striatum

The results obtained with synaptosomes suggest that the hyperactivity observed in $\alpha 6$ ^{L9'S} mice, which is eliminated or substantially reduced upon removal of $\alpha 4$ subunits, is due to differences in ACh-modulated DA release in striatum. Mid-brain DA neurons exhibit both tonic and phasic firing profiles, and the transition to phasic firing is governed in part by pontine cholinergic inputs to DA neuron cell bodies (Lança et al., 2000). DA neuron firing properties, in turn, strongly influence dopamine release. Therefore, we reasoned that $\alpha 6$ ^{L9'S} mice may demonstrate alterations in DA release as a result of $\alpha 6^*$ nAChR hypersensitivity in DA neurons.

To study striatal DA release in a preparation with intact DA fibers and functional ACh-modulation of DA release, we measured DA overflow with fast-scan cyclic voltammetry at carbon fiber electrodes (CFEs) in coronal striatal slices (Fig. 5A). We first calibrated the CFEs with solutions of DA dissolved in ACSF. Catecholamines such as DA and 5-HT produce characteristic oxidation and reduction voltage peaks (Zhou et al., 2005). DA detection was confirmed at our CFEs based on oxidation currents at +600 mV

and reduction currents at –200 mV, respectively (Fig. 5B, inset). Responses to pure DA were linear at our CFEs in the range of detection expected from striatal slices (0–5 μ M) (Fig. 5B). Electrically evoked DA release from dorsal striatum in slices revealed a voltammogram very similar to that of pure DA (Fig. 5C, inset).

Slice electrophysiological experiments in $\alpha 6$ ^{L9'S} tissue show that nicotine administration increases firing in DA neurons, and that spontaneous ACh release from cholinergic terminals produces a detectable activation of $\alpha 6$ ^{L9'S*} nAChRs on DA cell bodies (Drenan et al., 2008b) (data not shown). Endogenous ACh or exogenous nicotine may therefore augment DA neuron activity and result in more burst firing in $\alpha 6$ ^{L9'S} mice. Alternatively (or additionally), DA release from presynaptic terminals may be augmented due to enhanced activity of hypersensitive $\alpha 6^*$ receptors. To determine the interplay between DA release and DA neuron firing frequency, and to assess the role of $\alpha 4$ subunits, we measured DA release amplitude and kinetics in brain slices of WT,

$\alpha 6^{L9'S}$ and $\alpha 4KO/\alpha 6^{L9'S}$ mice. Because $\alpha 6^{L9'S}$ mice display a locomotor phenotype (Figs. 1, 2), we focused our experiments on dorsal striatum, the region most strongly implicated in motor function and the region dissected for the ST samples in the synaptosome experiments. We measured absolute DA release following single-pulse (1p) stimulation and four pulse (4p, 100 Hz) burst stimulation, which resembles the greatest firing rate for DA neurons in mammals (Hyland et al., 2002; Bayer and Glimcher, 2005). In WT slices, we noted a marked short-term synaptic depression for 4p stimulation compared to 1p [Fig. 5C (left), D], which is consistent with other reports using acutely cut slices (Schmitz et al., 2002; Rice and Cragg, 2004; Zhang and Sulzer, 2004; Exley et al., 2008). $\alpha 6^{L9'S}$ slices displayed a substantial reduction in peak DA release compared to WT 1p stimulation (WT 1p: $0.92 \pm 0.06 \mu M$; $\alpha 6^{L9'S}$ 1p: $0.34 \pm 0.05 \mu M$; $p < 0.001$) (Fig. 5C, middle panel). Unlike WT, however, $\alpha 6^{L9'S}$ slices did not show synaptic depression, as peak DA responses following 4p stimulation were significantly greater than for 1p stimulation (WT: 1p = $0.92 \pm 0.06 \mu M$; 4p = $1.04 \pm 0.11 \mu M$; $p > 0.05$) ($\alpha 6^{L9'S}$: 1p = $0.34 \pm 0.05 \mu M$; 4p = $0.94 \pm 0.19 \mu M$; $p < 0.01$) (Fig. 5C, D). Interestingly, we noted only a slight reduction in peak 1p DA release in $\alpha 4KO/\alpha 6^{L9'S}$ mice compared to WT (WT 1p: $0.92 \pm 0.06 \mu M$; $\alpha 4KO/\alpha 6^{L9'S}$ 1p: $0.70 \pm 0.08 \mu M$; $p < 0.05$) [Fig. 5C (right), D]. Removal of $\alpha 4$ subunits from $\alpha 6^{L9'S}$ mice recapitulated the synaptic depression phenomenon seen in WT slices, as 4p stimulation was slightly but not significantly elevated compared to 1p stimulation in $\alpha 4KO/\alpha 6^{L9'S}$ slices ($\alpha 4KO/\alpha 6^{L9'S}$: 1p = $0.70 \pm 0.08 \mu M$; 4p = $0.97 \pm 0.11 \mu M$; $p > 0.05$) [Fig. 5C (right), D]. Although neither 1p nor 4p peak DA responses in $\alpha 6^{L9'S}$ slices exceeded those in WT slices, we noted substantial alterations to the DA response waveform (Fig. 5C, middle panel) in experiments with $\alpha 6^{L9'S}$ tissue. To better understand the effect on DA waveforms caused by the $\alpha 6^{L9'S}$ mutation, we analyzed the responses in Figure 5C for 10–90% rise time and decay time constant (τ). In WT slices, there was no significant difference between 1p and 4p for rise time or τ (rise time: WT 1p = 317 ± 14 ms; WT 4p = 375 ± 33 ms; $p > 0.05$) (τ : WT 1p = 650 ± 82 ms; WT 4p = 842 ± 268 ms; $p > 0.05$) (Fig. 5E, F). In contrast, rise time following 1p stimulation in $\alpha 6^{L9'S}$ slices was substantially elevated compared to 1p (or 4p) responses in WT slices ($\alpha 6^{L9'S}$: 1p = 617 ± 70 ms; WT: 1p = 317 ± 17 ms; $p < 0.01$) ($\alpha 6^{L9'S}$: 1p = 617 ± 70 ms; WT: 4p = 375 ± 33 ms; $p < 0.01$) (Fig. 5E). Further, there was an additional increase in rise time for 4p responses compared to 1p in $\alpha 6^{L9'S}$ slices ($\alpha 6^{L9'S}$: 1p = 617 ± 70 ms; 4p = 804 ± 28 ms; $p < 0.05$) (Fig. 5E). τ values




Figure 5. $\alpha 4$ subunits mediate selective potentiation of burst-evoked striatal DA release in $\alpha 6^{L9'S}$ mice. **A**, Schematic of the slice recording experiment. A carbon fiber recording electrode (CFE) was placed in the dorsal striatum (CPu; bregma +0.4 mm), and DA release was evoked with a bipolar stimulating electrode placed 200–300 μm from the recording site. **B**, Calibration and testing of CFEs for DA detection. To show that CFE DA responses *in vitro* are linear, peak oxidative current was measured in response to bath solutions of 2.5 μM and 5.0 μM DA. A representative voltammogram is shown for an application of a solution of 5 μM dopamine to the carbon fiber surface (inset). **C**, Altered DA release responses in $\alpha 6^{L9'S}$ striatum are lost when $\alpha 4$ nAChR subunits are deleted. Coronal slices containing dorsal striatum were stimulated with a bipolar electrode and DA release was measured with fast scan cyclic voltammetry in WT, $\alpha 6^{L9'S}$, and $\alpha 4KO/\alpha 6^{L9'S}$ adult mice. Responses to 1 pulse (1p) and to 4p (100 Hz) stimulation were normalized to DA concentrations with calibration curves (**B**) for each genotype. Plots for each average response are shown in **C**. A representative voltammogram for evoked (1p) DA release in dorsal striatum is shown (inset). Scale bars: 300 nM DA, 500 ms. **D–G**, Statistics of peak responses and kinetic parameters from data in **C**. **D**, Peak DA responses in $\alpha 6^{L9'S}$ dorsal striatum are altered compared to WT and $\alpha 4KO/\alpha 6^{L9'S}$ mice. The average peak DA concentration (μM) for 1p and 4p stimulation is shown for each genotype. **E**, Rise time is prolonged for 4p DA responses in $\alpha 6^{L9'S}$ slices but is normalized by elimination of $\alpha 4$ nAChR subunits. In **E**, a box plot of 10–90% rise time for 1p and 4p DA responses is shown for WT, $\alpha 6^{L9'S}$, and $\alpha 4KO/\alpha 6^{L9'S}$ mice. **F**, Decay of extracellular DA is delayed following 4p stimulation in dorsal striatum of $\alpha 6^{L9'S}$ but not $\alpha 4KO/\alpha 6^{L9'S}$ mice. For each genotype indicated, τ was derived and plotted for mean 1p and 4p response curves (**F**). **G**, The relative DA signal is selectively elevated in $\alpha 6^{L9'S}$ striatum. 1p and 4p responses for each indicated genotype were integrated (area under the curve) and normalized to the WT 1p DA signal. For **C–G**, data are expressed as mean \pm SEM. The number of recording sites for each group was as follows: WT, $n = 11$; $\alpha 6^{L9'S}$, $n = 14$; $\alpha 4KO/\alpha 6^{L9'S}$, $n = 10$. All statistically significant comparisons are indicated. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

were also significantly increased for 4p versus 1p stimulation in $\alpha 6^{L9'S}$ slices ($\alpha 6^{L9'S}$: 1p = 824 ± 164 ms; 4p = 1990 ± 221 ms; $p < 0.01$) (Fig. 5F), suggesting that extracellular DA persists in $\alpha 6^{L9'S}$ dorsal striatum in response to a burst of action potentials. $\alpha 4$ subunits are apparently required for the effect seen in $\alpha 6^{L9'S}$ mice, as there was no significant effect on rise time or decay time constant in $\alpha 4KO/\alpha 6^{L9'S}$ mice when we compared 1p and 4p stimulation (rise time: $\alpha 4KO/\alpha 6^{L9'S}$ 1p = 305 ± 36 ms; $\alpha 4KO/\alpha 6^{L9'S}$ 4p = 362 ± 59 ms; $p > 0.05$) (τ : $\alpha 4KO/\alpha 6^{L9'S}$ 1p = 504 ± 131 ms; $\alpha 4KO/\alpha 6^{L9'S}$ 4p = 1019 ± 271 ms; $p > 0.05$) (Fig. 5E, F). We did notice significant differences in the maximum decay slope of the 1p and 4p responses among the three genotypes studied. WT DA responses exhibited the fastest DA uptake (i.e.,




Figure 6. Altered DA release probability in $\alpha 6^{L9S}$ dorsal striatum. **A**, Reduced initial release probability and elimination of paired-pulse depression in $\alpha 6^{L9S}$ striatum. Coronal slices from WT, $\alpha 6^{L9S}$ and $\alpha 4\text{KO}/\alpha 6^{L9S}$ mice were alternately stimulated with 1 pulse (1p) or 2 pulses (2p). 1p waveforms are measured directly as p_1 data, while the p_2 waveform was isolated by subtracting average 1p waveforms from average 2p waveforms over several trials. Average p_1 and p_2 waveforms for the indicated genotypes are shown in **A**. Calibration: 300 nM DA, 500 ms. **B**, Increased paired-pulse ratio in $\alpha 6^{L9S}$ mice versus WT controls and $\alpha 4\text{KO}/\alpha 6^{L9S}$ mice. For each dataset in **A**, paired-pulse ratio was calculated as p_2/p_1 . Data are expressed as mean \pm SEM. The number of recording sites for each group was as follows: WT, $n = 9$; $\alpha 6^{L9S}$, $n = 11$; $\alpha 4\text{KO}/\alpha 6^{L9S}$, $n = 9$. All statistically significant comparisons are indicated. $**p < 0.01$.

than peak measurements would suggest. Area-under-the-curve measurements (Zhang et al., 2009) for 1p and 4p responses in the three genotypes under study were normalized to WT 1p responses. Unlike WT and $\alpha 4\text{KO}/\alpha 6^{L9S}$ slices, $\alpha 6^{L9S}$ slices showed a significantly elevated 4p DA response compared to 1p stimulation (WT: $1p = 1.0 \pm 0.06$; $4p = 1.0 \pm 0.14$; $p > 0.05$) ($\alpha 6^{L9S}$: $1p = 0.5 \pm 0.1$; $4p = 1.6 \pm 0.3$; $p < 0.001$) ($\alpha 4\text{KO}/\alpha 6^{L9S}$: $1p = 0.8 \pm 0.1$; $4p = 1.1 \pm 0.2$; $p > 0.05$) (Fig. 5G).

To further isolate and study the effect of the $\alpha 6^{L9S}$ mutation and DA neuron firing frequency on evoked DA release, we conducted paired-pulse experiments. In dorsal striatum, DA release displays marked short-term synaptic depression when pulses are paired at frequencies from 1 to 100 Hz (Cragg, 2003; Rice and Cragg, 2004; Zhang and Sulzer, 2004). In nucleus accumbens, however, initial release probability is lower but paired-pulse depression is not as severe (Cragg, 2003; Zhang et al., 2009). In WT dorsal striatum, we also measured significant synaptic depression comparing a first pulse (p_1 ; $0.89 \pm 0.21 \mu\text{M}$ DA) with a second (p_2 ; $0.09 \pm 0.05 \mu\text{M}$ DA) (Fig. 6A, left). In contrast, experiments in $\alpha 6^{L9S}$ slices revealed no synaptic depression, as peak $[\text{DA}]_o$ was approximately equivalent for p_1 ($0.20 \pm 0.03 \mu\text{M}$ DA) and p_2 ($0.19 \pm 0.05 \mu\text{M}$ DA) (Fig. 6A, middle). This lack of synaptic depression was reflected in a significantly increased paired-pulse ratio for $\alpha 6^{L9S}$ mice versus WT (WT: 0.13 ± 0.06 ; $\alpha 6^{L9S}$: 0.67 ± 0.15 ; $p < 0.01$) (Fig. 6B). Again, the gain in synaptic facilitation afforded by the $\alpha 6^{L9S}$ mutation was completely reversed by loss of $\alpha 4$ subunits: $\alpha 4\text{KO}/\alpha 6^{L9S}$ p_1 peak DA ($0.85 \pm 0.13 \mu\text{M}$ DA) returned to WT levels, p_2 responses ($0.14 \pm 0.10 \mu\text{M}$ DA) were similar to those seen in WT, and the paired-pulse ratio for $\alpha 4\text{KO}/\alpha 6^{L9S}$ release (0.12 ± 0.09) was comparable to WT (Fig. 6A, B). Thus, together, these electrochemical experiments suggest that patterns of tonic and phasic activity in DA neuron firing in $\alpha 6^{L9S}$ mice results in substantially altered patterns of DA release, from reduced DA release during tonic firing to augmented synaptic DA during phasic firing.




Figure 7. Normal DA transporter and DA receptor number and function in $\alpha 6^{L9S}$ and $\alpha 4\text{KO}/\alpha 6^{L9S}$ mice. **A–C**, Normal DA-related pharmacological parameters in $\alpha 6^{L9S}$ and $\alpha 4\text{KO}/\alpha 6^{L9S}$ mice as determined by DAT and DA receptor ligand binding. Brain regions (OT and ST) from WT, $\alpha 6^{L9S}$, $\alpha 4\text{KO}$, and $\alpha 4\text{KO}/\alpha 6^{L9S}$ mice were dissected and labeled with the indicated ligand followed by washout and quantification by scintillation counting. Raw binding values are indicated as fmol/mg protein for mazindol (DAT ligand), SCH23390 (D₁ receptor ligand), and raclopride (D₂ receptor ligand). **D, E**, Normal DA transporter function in $\alpha 6^{L9S}$ and $\alpha 4\text{KO}/\alpha 6^{L9S}$ mice. Synaptosomes were prepared as in Figure 2, but [³H]dopamine uptake was assayed at 50 nM (**D**) or 1 μM (**E**) [DA]_o for all genotypes. **F**, Ratio of DAT activity at 1 μM (“high”) versus 50 nM (“low”) [DA]_o. Data are ratios of the values in **D** and **E**. Data are expressed as mean \pm SEM. The number of mice in each group was as follows: $n = 9$; $\alpha 6^{L9S}$, $n = 9$; $\alpha 4\text{KO}$, $n = 8$; $\alpha 4\text{KO}/\alpha 6^{L9S}$, $n = 8$. All statistically significant comparisons are indicated. $*p < 0.05$.

greatest negative-going maximum decay slope) (1p, $-0.00100 \pm 0.00007 \mu\text{M}/\text{ms}$; 4p, $-0.00120 \pm 0.00017 \mu\text{M}/\text{ms}$), $\alpha 6^{L9S}$ responses were the slowest (1p, $-0.00006 \pm 0.00003 \mu\text{M}/\text{ms}$; 4p, $-0.00028 \pm 0.00002 \mu\text{M}/\text{ms}$), and $\alpha 4\text{KO}/\alpha 6^{L9S}$ responses exhibited an intermediate value (1p, $-0.00043 \pm 0.00008 \mu\text{M}/\text{ms}$; 4p, $-0.00053 \pm 0.00011 \mu\text{M}/\text{ms}$). Maximum decay slope indicates the speed of DA uptake at a saturating concentration of DA, thus these differences may reflect changes in DA transporter V_{max} (see Discussion). The prolonged decay kinetics seen in 1p and 4p DA release responses in $\alpha 6^{L9S}$ slices (Fig. 5F) suggested that the integrated DA response in these mice may differ more substantially

release, from reduced DA release during tonic firing to augmented synaptic DA during phasic firing.

DA release and uptake, as well as a variety of mouse behaviors, can be influenced by alterations in components of the DA system such as D₁-class and D₂-class dopamine receptors and the dopamine transporter (DAT). In particular, DA synaptic lifetime in ST is strongly influenced by the rate of uptake by DAT (Giros et al., 1996; Zhuang et al., 2001; Rice and Cragg, 2008). Further, mice lacking D₂ receptors have a decreased peak and duration of DA release in response to single pulses (Schmitz et al., 2002). To determine whether any substantial alterations in these compo-

nents of the DA system might account for our behavioral or physiological results, we measured DAT and D₁ and D₂ DA receptors by ligand binding in tissue homogenates. In ST, there were no differences in DAT levels as determined by [³H]-mazindol binding (Fig. 7A), whereas we did note an increase in DAT levels in $\alpha 6^{L9'S}$ OT versus WT OT (WT = 1083 ± 102 fmol/mg protein; $\alpha 6^{L9'S}$ = 1503 ± 191 fmol/mg protein; $p < 0.05$) (Fig. 7A). For D₁-class receptors, there was no statistically significant difference in [³H]SCH23390 ligand binding for any genotype comparison in either OT or ST (Fig. 7B). Similarly, there was also no significant difference in D₂-class receptors (measured with [³H]raclopride) in OT or ST for any genotype comparison (Fig. 7C). We took note of the overall reduction in DAT and D₂ receptor levels in the ventral relative to dorsal striatum, which is consistent with a recent report (Lammel et al., 2008). To directly measure DAT function *in vitro*, we performed DAT uptake assays using synaptosomes similar to those used for DA release. Using established methods for determining DAT function (Grady et al., 2002), we estimated DAT K_M to be 80 nM DA (data not shown), which was consistent with previous studies (Giros et al., 1996; Parish et al., 2005). At a [DA]_o close to the K_M (50 nM), and at a maximal [DA]_o (1 μ M), there was little effect on DA uptake for any genotype comparison (Fig. 7D,E). Interestingly, these two concentrations of DA roughly correspond to the EC₅₀ for activation of D₂ and D₁ receptors, respectively. There was a significant difference between $\alpha 4$ KO and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ only in OT but not ST, and only at 1.0 μ M [DA]_o ($\alpha 4$ KO = 6.4 ± 0.8 pmol of DA/ μ g protein/min; $\alpha 4$ KO/ $\alpha 6^{L9'S}$ = 4.3 ± 0.4 pmol of DA/ μ g protein/min; $p < 0.05$) (Fig. 7E). There was no difference in either brain region for any genotype comparison for the 1.0 μ M [DA]_o (~20 × K_M)/0.05 μ M [DA]_o (~ K_M) ratio of uptake rates (Fig. 7F).

Discussion

Overall, these data are consistent with the idea that cholinergic control over DA release exerts greater influence in $\alpha 6^{L9'S}$ mice due to $\alpha 6^*$ nAChR hypersensitivity (Fig. 8). Similar to other *in vitro* electrochemistry studies, we show that in WT dorsal striatum, single stimulus pulses or brief trains in DA fibers elicit similar levels of DA release due to short-term synaptic depression (Fig. 8A). Several reports show that decreased presynaptic nAChR activity, via desensitization, pharmacological blockade, or decreased ACh release from striatal cholinergic interneurons, can alter short-term depression and enhance the difference in efficacy between single pulses and bursts (Zhou et al., 2001; Rice and Cragg, 2004; Zhang and Sulzer, 2004; Threlfell et al., 2010). In this study, increased nAChR function can also enhance this difference. In mice with hypersensitive $\alpha 6^{L9'S*}$ nAChRs, single APs combine with nAChR activity to result in reduced DA release (Fig. 8B). In these mice, however, released DA is present for longer periods (Fig. 5E,F), paired-pulse depression (PPD) is reduced (Fig. 6B), and bursts of APs lead to more overall DA release (Fig. 5G).

In some respects, our electrochemistry results in dorsal striatum, where DA release following single-pulse stimulation in $\alpha 6^{L9'S}$ slices is reduced and PPD is relieved relative to WT and $\alpha 4$ KO/ $\alpha 6^{L9'S}$ tissue, resembles experiments where nAChR activity is blocked before DA fiber stimulation. Indeed, reducing striatal nAChR activity with desensitizing applications of nicotine or antagonists such as dihydro- β -erythroidine (DH β E) or mecamylamine results in less DA release in response to a single stimulus (Zhou et al., 2001; Rice and Cragg, 2004; Zhang and Sulzer, 2004). These studies also demonstrate that PPD is sub-




Figure 8. Hypersensitive $\alpha 6^*$ nAChRs mediate sustained burst-evoked DA release in $\alpha 6^{L9'S}$ mouse striatum. **A**, Single pulse and burst firing in DA fibers of WT mice. DA release from DA terminals is governed by the pattern of firing activity in DA axons (single pulse vs burst). Local ACh from cholinergic interneurons acts at presynaptic nAChRs, including $\alpha 6^*$, to modulate the probability of release. **B**, Single pulse and burst firing in DA fibers of $\alpha 6^{L9'S}$ mice. Based on the data presented here, single pulses in DA fibers collaborate with nAChR activity in the terminal to reduce the 1p DA response. The combination of (1) a burst of APs and (2) ACh-driven activation of hypersensitive $\alpha 6^*$ receptors results in augmented DA release compared to single-pulse stimulation.

stantially reduced when nAChR activity is eliminated by these applications. We see a similar result in $\alpha 6^{L9'S}$ slices relative to WT: reduced peak DA release following single stimulations (Figs. 5C, 6A). We also noted that the DA release profile in $\alpha 6^{L9'S}$ dorsal striatum is similar in some respects to the profile in DA D₂ receptor KO mice. In these mice, as in ours, DA release following single-pulse stimulation is reduced relative to WT mice (Schmitz et al., 2002). Interestingly, our results in $\alpha 6^{L9'S}$ dorsal striatum more closely resemble the normal pattern of DA release in ventral striatum of mice and primates. Electrochemical recordings in nucleus accumbens shell of mice (Zhang et al., 2009) or primates (Cragg, 2003) reveals that ventral regions of the striatum are characterized by reduced peak DA release following single stimulation, and paired-pulse results showing little PPD or even paired-pulse facilitation. This is thought to occur via differences in Ca²⁺ availability in presynaptic terminals of these two brain areas. Thus, in some respects our DA release results in $\alpha 6^{L9'S}$ mice are quite similar to various studies, including reports using pharmacological agents or other genetic mutations to manipulate the DA system, as well as reports in different species.

In other respects, however, our electrochemical results differ from previous studies. For example, whereas many studies involving elimination of nAChR activity demonstrate that brief trains (e.g., 4p) result in augmented peak DA release compared to identical stimulations under control conditions (Rice and Cragg, 2004; Exley et al., 2008; Zhang et al., 2009), we did not see an

increase in peak DA relative to WT slices following 4p stimulus protocols (Fig. 5D). Most importantly, though, DA waveforms in $\alpha 6^{L9'S}$ dorsal striatum display novel kinetics. We report that DA responses in $\alpha 6^{L9'S}$ dorsal striatum are slower to reach peak concentration (Fig. 5E), and also decay more slowly following cessation of the stimulus (Fig. 5F). These effects on DA kinetics are not seen in studies where nAChR activity is altered with pharmacological agents, and are typically only apparent when the DA transporter is genetically eliminated/reduced, or pharmacologically blocked (Giros et al., 1996; Zhuang et al., 2001; Cragg, 2003; Senior et al., 2008; Zhang et al., 2009).

What causes the altered DA release pattern seen in $\alpha 6^{L9'S}$ dorsal striatum? ACh release from cholinergic interneurons, perhaps augmented by electrical stimulation of the tissue, may play a role in $\alpha 6^{L9'S}$ altered DA release, likely via differences in receptor sensitivity to ligand (Fig. 4H). Although intrinsic differences in ACh release probability (and consequent $\alpha 6^*$ nAChR activation) by cholinergic interneurons in intact $\alpha 6^{L9'S}$ versus WT mice are possible, WT and $\alpha 6^{L9'S}$ cholinergic interneurons have equivalent firing rates and largely similar membrane properties (Drenan et al., 2008b). We cannot rule out that compensatory or adaptive mechanisms, operating as the animals mature, might cause the reduced 1p release and/or prolonged release kinetics. For instance, $\alpha 6^{L9'S}$ presynaptic terminals may have undergone a change in their channel repertoire that renders them hypersensitive to repetitive stimulation. Changes in the ratio of $\alpha 4^*$ (non- $\alpha 6$)/ $\alpha 6^*$ function, which are present in $\alpha 6^{L9'S}$ mice, may be such an adaptation. Alternatively, the reduction in peak DA release following single and/or burst stimulation may be an adaptive response to the prolonged release kinetics, similar to DAT KO mice (Giros et al., 1996).

In a previous study, we showed that hypersensitive $\alpha 6^{L9'S}$ channels are tonically active in DA neuron somata (Drenan et al., 2008b), suggesting that tonic cholinergic input to midbrain DA areas may depolarize DA neurons and/or increase their firing rate *in vivo*. Furthermore, ligand-gated cation currents through $\alpha 6^{L9'S}$ channels in these cells are prolonged compared to their WT counterparts (Drenan et al., 2008b), which reflects the significant increase in single channel burst duration in nAChRs with L9'S mutations (Labarca et al., 1995). In striatum, presynaptic and/or axonal $\alpha 6^{L9'S}$ channels may similarly depolarize DA fibers/terminals due to these changes at the single channel level. Axonal depolarization can significantly alter the action potential waveform (Shu et al., 2006; Kole et al., 2007), and tonic depolarization of the presynaptic terminal would be expected to reduce V_{max} for the DA transporter (Huang et al., 1999), resulting in slower DA reuptake following release. Indeed, in PC12 cells expressing DAT and nAChRs, nAChR activation resulted in membrane depolarization and a reduction in DAT uptake velocity (Huang et al., 1999). Although our DAT binding and functional experiments show that there are no intrinsic differences in DAT expression levels or enzymatic function *in vitro* in the four genotypes examined (Fig. 7), they do not address the possibility that $\alpha 6^{L9'S}$ channels depolarize DA fibers and reduce DAT function in slices and/or *in vivo*. Alternatively, $\alpha 6^{L9'S}$ DA fibers may have normal resting membrane potentials but undergo prolonged depolarization (due to activation of $\alpha 6^{L9'S}$ channels by ACh) during electrical stimulation of the slice, resulting in extended periods of slowed DAT uptake velocity during the time scale of our measurements.

Future studies are needed to fully determine the mechanism that gives rise to the alterations in DA release seen in $\alpha 6^{L9'S}$ dorsal striatum. It is important to note that, unlike *in vitro* slice experi-

ments, studies of DA release *in vivo* are characterized by much smaller DA signals (Michael and Wightman, 1999) and do not show substantial synaptic depression (Chergui et al., 1994). Thus, it will be important to study DA neuron firing and DA release in awake, behaving $\alpha 6^{L9'S}$ mice in future studies. Nevertheless, these alterations along with changes in excitability of DA neuron cell bodies in midbrain are sufficient to cause the complex behavioral phenotypes that were observed in $\alpha 6^{L9'S}$ mice. We suggest that $\alpha 6^{L9'S}$ mouse behavioral hyperactivity results from both (1) a more efficacious action of ACh on DA neuron dendrites and somata harboring hypersensitive $\alpha 6\alpha 4\beta 2^*$ channels, resulting in more phasic firing, and (2) DA fibers in striatum that have more effective frequency filtering (Exley and Cragg, 2008; Exley et al., 2008), where activation of $\alpha 6^{L9'S}$ channels by ACh permits DA fibers to diminish their output in response to tonic firing yet augment DA release in response to bouts of phasic firing. In contrast to other recent studies that amplify and isolate phasic DA neuron firing to alter DA-dependent behaviors with gene knock-outs (Zweifel et al., 2009) and optogenetics (Tsai et al., 2009), we show that the cholinergic system can be manipulated to alter DA release and modify a variety of behaviors in mammals.

More specifically, this study demonstrates the importance of $\alpha 6\alpha 4\beta 2^*$ nAChRs in governing cholinergic control over DA release, and reinforces the idea that compounds capable of selectively targeting $\alpha 6\alpha 4\beta 2^*$ nAChRs could be useful in manipulating the DA system in disorders such as nicotine dependence, PD, schizophrenia, or attention deficit hyperactivity disorder. Such drug therapies that regulate dopaminergic output via modification of somatic and/or presynaptic $\alpha 6\alpha 4\beta 2^*$ receptors may give better outcomes than DA agonists or DA replacement therapies, as the natural spatiotemporal activity patterns of DA neurons would be better preserved. For example, stimulating DA release with $\alpha 6\alpha 4\beta 2^*$ selective compounds in PD may alleviate dyskinesias associated with L-Dopa therapy if coadministration of the nAChR compound allowed the clinician to reduce the necessary dose of L-Dopa (Quik and McIntosh, 2006; Quik et al., 2008; Bordia et al., 2010).

References

- Akopian G, Crawford C, Beal MF, Cappelletti M, Jakowec MW, Petzinger GM, Zheng L, Gheorghie SL, Reichel CM, Chow R, Walsh JP (2008) Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia. *J Neurosci* 28:9585–9597.
- Azam L, Winzer-Serhan UH, Chen Y, Leslie FM (2002) Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. *J Comp Neurol* 444:260–274.
- Bayer HM, Glimcher PW (2005) Midbrain dopamine neurons encode a quantitative reward prediction error signal. *Neuron* 47:129–141.
- Bordia T, Campos C, McIntosh JM, Quik M (2010) Nicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitization. *J Pharmacol Exp Ther* 333:929–938.
- Brown RW, Collins AC, Lindstrom JM, Whiteaker P (2007) Nicotinic $\alpha 5$ subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. *J Neurochem* 103:204–215.
- Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM, McIntosh JM (1996) A new α -conotoxin which targets $\alpha 3\beta 2$ nicotinic acetylcholine receptors. *J Biol Chem* 271:7522–7528.
- Champtiaux N, Han ZY, Bessis A, Rossi FM, Zoli M, Marubio L, McIntosh JM, Changeux JP (2002) Distribution and pharmacology of $\alpha 6$ -containing nicotinic acetylcholine receptors analyzed with mutant mice. *J Neurosci* 22:1208–1217.
- Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Léna C, Clementi F, Moretti M, Rossi FM, Le Novère N, McIntosh JM, Gardier AM, Changeux JP (2003) Subunit composition of functional nicotinic

- receptors in dopaminergic neurons investigated with knock-out mice. *J Neurosci* 23:7820–7829.
- Chergui K, Suaud-Chagny MF, Gonon F (1994) Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. *Neuroscience* 62:641–645.
- Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, et al. (2005) Varenicline: an $\alpha 4\beta 2$ nicotinic receptor partial agonist for smoking cessation. *J Med Chem* 48:3474–3477.
- Cragg SJ (2003) Variable dopamine release probability and short-term plasticity between functional domains of the primate striatum. *J Neurosci* 23:4378–4385.
- Cui C, Booker TK, Allen RS, Grady SR, Whiteaker P, Marks MJ, Salminen O, Tritto T, Butt CM, Allen WR, Stitzel JA, McIntosh JM, Boulter J, Collins AC, Heinemann SF (2003) The $\beta 3$ nicotinic receptor subunit: a component of α -Conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. *J Neurosci* 23:11045–11053.
- Drenan RM, Nashmi R, Imoukhuede P, Just H, McKinney S, Lester HA (2008a) Subcellular trafficking, pentameric assembly, and subunit stoichiometry of neuronal nicotinic acetylcholine receptors containing fluorescently labeled $\alpha 6$ and $\beta 3$ subunits. *Mol Pharmacol* 73:27–41.
- Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, Marks MJ, Lester HA (2008b) In vivo activation of midbrain dopamine neurons via sensitized, high-affinity $\alpha 6^*$ nicotinic acetylcholine receptors. *Neuron* 60:123–136.
- Exley R, Cragg SJ (2008) Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. *Br J Pharmacol* 153 [Suppl 1]:S283–S297.
- Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ (2008) $\alpha 6$ -containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. *Neuropsychopharmacology* 33:2158–2166.
- Gahring LC, Persiyanov K, Rogers SW (2004) Neuronal and astrocyte expression of nicotinic receptor subunit $\beta 4$ in the adult mouse brain. *J Comp Neurol* 468:322–333.
- Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature* 379:606–612.
- Gotti C, Moretti M, Clementi F, Riganti L, McIntosh JM, Collins AC, Marks MJ, Whiteaker P (2005) Expression of nigrostriatal $\alpha 6$ -containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by $\beta 3$ subunit gene deletion. *Mol Pharmacol* 67:2007–2015.
- Grady SR, Murphy KL, Cao J, Marks MJ, McIntosh JM, Collins AC (2002) Characterization of nicotinic agonist-induced [^3H]dopamine release from synaptosomes prepared from four mouse brain regions. *J Pharmacol Exp Ther* 301:651–660.
- Huang CL, Chen HC, Huang NK, Yang DM, Kao LS, Chen JC, Lai HL, Chern Y (1999) Modulation of dopamine transporter activity by nicotinic acetylcholine receptors and membrane depolarization in rat pheochromocytoma PC12 cells. *J Neurochem* 72:2437–2444.
- Hyland BI, Reynolds JN, Hay J, Perk CG, Miller R (2002) Firing modes of midbrain dopamine cells in the freely moving rat. *Neuroscience* 114:475–492.
- Ikemoto S (2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. *Brain Res Rev* 56:27–78.
- Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP (2001) Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. *J Neurosci* 21:1452–1463.
- Kole MH, Letzkus JJ, Stuart GJ (2007) Axon initial segment Kv1 channels control axonal action potential waveform and synaptic efficacy. *Neuron* 55:633–647.
- Labarca C, Nowak MW, Zhang H, Tang L, Deshpande P, Lester HA (1995) Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors. *Nature* 376:514–516.
- Lammel S, Hetzel A, Häckel O, Jones I, Liss B, Roeper J (2008) Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. *Neuron* 57:760–773.
- Lança AJ, Adamson KL, Coen KM, Chow BL, Corrigan WA (2000) The pedunculopontine tegmental nucleus and the role of cholinergic neurons in nicotine self-administration in the rat: a correlative neuroanatomical and behavioral study. *Neuroscience* 96:735–742.
- Marks MJ, Whiteaker P, Collins AC (2006) Deletion of the $\alpha 7$, $\beta 2$, or $\beta 4$ nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [^3H]epibatidine. *Mol Pharmacol* 70:947–959.
- Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, McIntosh JM, Rossi F, Champiaux N, Zoli M, Changeux JP (2003) Effects of nicotine in the dopaminergic system of mice lacking the $\alpha 4$ subunit of neuronal nicotinic acetylcholine receptors. *Eur J Neurosci* 17:1329–1337.
- Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, Evrard A, Cazala P, Cormier A, Mameli-Engvall M, Dufour N, Cloëz-Tayarani I, Bemelmans AP, Mallet J, Gardier AM, David V, Faure P, Granon S, Changeux JP (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. *Nature* 436:103–107.
- Michael DJ, Wightman RM (1999) Electrochemical monitoring of biogenic amine neurotransmission in real time. *J Pharm Biomed Anal* 19:33–46.
- Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, Huang Q, McClure-Begley T, Lindstrom JM, Labarca C, Collins AC, Marks MJ, Lester HA (2007) Chronic nicotine cell specifically upregulates functional $\alpha 4^*$ nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. *J Neurosci* 27:8202–8218.
- Parish CL, Nunan J, Finkelstein DI, McNamara FN, Wong JY, Waddington JL, Brown RM, Lawrence AJ, Horne MK, Drago J (2005) Mice lacking the $\alpha 4$ nicotinic receptor subunit fail to modulate dopaminergic neuronal arbors and possess impaired dopamine transporter function. *Mol Pharmacol* 68:1376–1386.
- Piccio MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the $\beta 2$ subunit are involved in the reinforcing properties of nicotine. *Nature* 391:173–177.
- Quik M, McIntosh JM (2006) Striatal $\alpha 6^*$ nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. *J Pharmacol Exp Ther* 316:481–489.
- Quik M, O'Leary K, Tanner CM (2008) Nicotine and Parkinson's disease: implications for therapy. *Mov Disord* 23:1641–1652.
- Rice ME, Cragg SJ (2004) Nicotine amplifies reward-related dopamine signals in striatum. *Nat Neurosci* 7:583–584.
- Rice ME, Cragg SJ (2008) Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. *Brain Res Rev* 58:303–313.
- Ross SA, Wong JY, Clifford JJ, Kinsella A, Massalas JS, Horne MK, Scheffer IE, Kola I, Waddington JL, Berkovic SF, Drago J (2000) Phenotypic characterization of an $\alpha 4$ neuronal nicotinic acetylcholine receptor subunit knock-out mouse. *J Neurosci* 20:6431–6441.
- Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, Collins AC, Grady SR (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. *Mol Pharmacol* 65:1526–1535.
- Salminen O, Whiteaker P, Grady SR, Collins AC, McIntosh JM, Marks MJ (2005) The subunit composition and pharmacology of α -Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay. *Neuropharmacology* 48:696–705.
- Salminen O, Drapeau JA, McIntosh JM, Collins AC, Marks MJ, Grady SR (2007) Pharmacology of α -conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. *Mol Pharmacol* 71:1563–1571.
- Schmitz Y, Schmauss C, Sulzer D (2002) Altered dopamine release and uptake kinetics in mice lacking D_2 receptors. *J Neurosci* 22:8002–8009.
- Schulte A, Chow RH (1996) A simple method for insulating carbon-fiber microelectrodes using anodic electrophoretic deposition of paint. *Anal Chem* 68:3054–3058.
- Senior SL, Ninkina N, Deacon R, Bannerman D, Buchman VL, Cragg SJ, Wade-Martins R (2008) Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. *Eur J Neurosci* 27:947–957.
- Shu Y, Hasenstaub A, Duque A, Yu Y, McCormick DA (2006) Modulation of intracortical synaptic potentials by presynaptic somatic membrane potential. *Nature* 441:761–765.
- Steele AD, Jackson WS, King OD, Lindquist S (2007) The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. *Proc Natl Acad Sci U S A* 104:1983–1988.

- Steele AD, Hutter G, Jackson WS, Heppner FL, Borkowski AW, King OD, Raymond GJ, Aguzzi A, Lindquist S (2008) Heat shock factor 1 regulates lifespan as distinct from disease onset in prion disease. *Proc Natl Acad Sci U S A* 105:13626–13631.
- Tapper AR, McKinney SL, Marks MJ, Lester HA (2007) Nicotine responses in hypersensitive and knockout $\alpha 4$ mice account for tolerance to both hypothermia and locomotor suppression in wild-type mice. *Physiol Genomics* 31:422–428.
- Threlfell S, Clements MA, Khodai T, Pienaar IS, Exley R, Wess J, Cragg SJ (2010) Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. *J Neurosci* 30:3398–3408.
- Tsai HC, Zhang F, Adamantidis A, Stuber GD, Bonci A, de Lecea L, Deisseroth K (2009) Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. *Science* 324:1080–1084.
- Xiao C, Nashmi R, McKinney S, Cai H, McIntosh JM, Lester HA (2009) Chronic nicotine selectively enhances $\alpha 4\beta 2^*$ nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. *J Neurosci* 29:12428–12439.
- Zhang H, Sulzer D (2004) Frequency-dependent modulation of dopamine release by nicotine. *Nat Neurosci* 7:581–582.
- Zhang T, Zhang L, Liang Y, Siapas AG, Zhou FM, Dani JA (2009) Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. *J Neurosci* 29:4035–4043.
- Zhou FM, Liang Y, Dani JA (2001) Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. *Nat Neurosci* 4:1224–1229.
- Zhou FM, Liang Y, Salas R, Zhang L, De Biasi M, Dani JA (2005) Corelease of dopamine and serotonin from striatal dopamine terminals. *Neuron* 46:65–74.
- Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R (2001) Hyperactivity and impaired response habituation in hyperdopaminergic mice. *Proc Natl Acad Sci U S A* 98:1982–1987.
- Zweifel LS, Parker JG, Lobb CJ, Rainwater A, Wall VZ, Fadok JP, Darvas M, Kim MJ, Mizumori SJ, Paladini CA, Phillips PE, Palmiter RD (2009) Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. *Proc Natl Acad Sci U S A* 106:7281–7288.